EP0784690B1
(fr)
*
|
1994-06-10 |
2006-08-16 |
Genvec, Inc. |
Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
EP0760682A4
(fr)
|
1995-02-28 |
1998-09-09 |
Univ California |
Therapie angiogenique par transfert de genes
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
*
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
ES2333425T5
(es)
*
|
1995-06-15 |
2012-08-28 |
Crucell Holland B.V. |
Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
WO1998013499A2
(fr)
*
|
1996-09-25 |
1998-04-02 |
Novartis Ag |
Lignees cellulaires d'emballage permettant de faciliter le developpement de vecteurs adenoviraux d'une grande capacite
|
WO1998032859A1
(fr)
*
|
1997-01-29 |
1998-07-30 |
Cornell Research Foundation, Inc. |
Administration a des sites multiples d'un vecteur d'adenovirus en vue de provoquer une angiogenese
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US6348450B1
(en)
*
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
CA2340276A1
(fr)
|
1998-08-28 |
2000-03-09 |
Duke University |
Adenovirus a deletions dans les sequences iva2, 100k et/ou de proteines preterminales
|
US6303362B1
(en)
*
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
WO2001007571A1
(fr)
*
|
1999-04-23 |
2001-02-01 |
Introgene B.V. |
Systemes et procedes de transfert d'acide nucleique
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
US6793926B1
(en)
|
1999-05-27 |
2004-09-21 |
Genovo, Inc. |
Methods for production of a recombinant adeno-associated virus
|
US6627190B2
(en)
*
|
1999-07-12 |
2003-09-30 |
Saint Louis University |
Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
|
US6613516B1
(en)
*
|
1999-10-30 |
2003-09-02 |
Affymetrix, Inc. |
Preparation of nucleic acid samples
|
US6867022B1
(en)
|
2000-01-21 |
2005-03-15 |
Regents Of The University Of Michigan |
Replication deficient adenovirus vectors and methods of making and using them
|
US7653769B2
(en)
*
|
2006-12-14 |
2010-01-26 |
International Business Machines Corporation |
Management of devices connected to infiniband ports
|
US6821775B1
(en)
*
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
US6591543B2
(en)
*
|
2000-04-14 |
2003-07-15 |
Kenneth P. Sabine |
Top water lure with highly active propeller
|
KR20030072214A
(ko)
|
2000-05-26 |
2003-09-13 |
스미또모 세이야꾸 가부시키가이샤 |
완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터
|
US6579522B1
(en)
|
2000-06-27 |
2003-06-17 |
Genvec, Inc. |
Replication deficient adenoviral TNF vector
|
EP1203819A3
(fr)
*
|
2000-10-06 |
2002-08-07 |
Transgene S.A. |
Vecteurs anti-inflammatoires
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
CA2460157A1
(fr)
|
2001-09-18 |
2003-03-27 |
Clontech Laboratories, Inc. |
Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site
|
US20030087438A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
E1-revertant-free adenoviral composition
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
US20030158112A1
(en)
*
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
JP2005536231A
(ja)
*
|
2002-05-08 |
2005-12-02 |
イントロン,インコーポレーテッド |
アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用
|
WO2004038380A2
(fr)
*
|
2002-10-23 |
2004-05-06 |
Intronn, Inc. |
Procedes de criblage destines a identifier des molecules de pre-trans-epissage efficaces
|
JP2006516027A
(ja)
*
|
2002-12-02 |
2006-06-15 |
ジェンベク、インコーポレイティッド |
眼関連障害の治療用材料および治療方法
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
CA2522380A1
(fr)
*
|
2003-03-19 |
2004-09-30 |
Isogenis, Inc. |
Inhibition specifique du rejet d'allogreffe
|
ES2391975T3
(es)
*
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Vacunas a base de vector adenovírico
|
WO2005051432A1
(fr)
*
|
2003-11-14 |
2005-06-09 |
Genvec, Inc. |
Regime therapeutique pour le traitement du cancer
|
BRPI0416920A
(pt)
*
|
2003-11-24 |
2007-01-23 |
Canji Inc |
redução de cicatriz dérmica
|
WO2005070948A1
(fr)
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction de defauts genetiques lies a l'alpha-1-antitrypsine par transepissage d'arn a mediation par spliceosome
|
US20060177933A1
(en)
*
|
2004-01-23 |
2006-08-10 |
Madaiah Puttaraju |
Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
EP1718738A2
(fr)
*
|
2004-02-23 |
2006-11-08 |
Crucell Holland B.V. |
Procedes de purification de virus
|
WO2005089811A1
(fr)
*
|
2004-03-12 |
2005-09-29 |
Genvec, Inc. |
Materiaux pour traiter des fuites vasculaires dans l'oeil
|
US20070207166A1
(en)
|
2004-04-12 |
2007-09-06 |
Genvec, Inc. |
Method of Using Adenoviral Vectors to Induce an Immune Response
|
US20090053249A1
(en)
*
|
2004-07-20 |
2009-02-26 |
Yan Qi |
Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
WO2006039045A2
(fr)
*
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methode d'utilisation de vecteurs adenoviraux presentant une immunogenicite accrue in vivo
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
JP5053850B2
(ja)
*
|
2004-10-08 |
2012-10-24 |
バークシス コーポレーション |
抗体遺伝子導入および抗体ポリペプチド産生のためのrnaトランススプライシングの使用
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
US20060188481A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Saitama Medical School |
Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
|
CN101163494A
(zh)
|
2005-02-23 |
2008-04-16 |
Uab研究基金会 |
烷基糖苷增强的接种
|
CN101155915B
(zh)
*
|
2005-04-11 |
2013-12-04 |
克鲁塞尔荷兰公司 |
利用超滤进行病毒纯化
|
BRPI0615400A2
(pt)
*
|
2005-08-31 |
2011-05-17 |
Genvec Inc |
vacinas para malária baseadas em vetor adenoviral
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
BRPI0618441B8
(pt)
*
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
vetor adenoviral
|
EP2114445A2
(fr)
*
|
2007-01-09 |
2009-11-11 |
Genvec, Inc. |
Vaccins antipaludeens a base de vecteur adenoviral
|
US20090227031A1
(en)
*
|
2007-03-09 |
2009-09-10 |
Imre Kovesdi |
Cells for adenovirus vector and protein production
|
US20100263066A1
(en)
*
|
2007-04-30 |
2010-10-14 |
Medtronic, Inc |
Inert dna sequences for efficient viral packaging and methods of use
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
US8871515B2
(en)
*
|
2008-09-17 |
2014-10-28 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
PL2350268T3
(pl)
*
|
2008-11-03 |
2015-05-29 |
Crucell Holland Bv |
Sposób wytwarzania wektorów adenowirusowych
|
WO2011045378A1
(fr)
|
2009-10-15 |
2011-04-21 |
Crucell Holland B.V. |
Procédé de purification de particules d'adénovirus
|
PL2488635T3
(pl)
|
2009-10-15 |
2014-04-30 |
Crucell Holland Bv |
Proces do oczyszczania adenowirusa z hodowli o dużej gęstości komórek
|
WO2011047316A1
(fr)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Séquences d'acides nucléiques codant pour des protéines mosaïques extensibles du vih
|
US9133248B2
(en)
|
2009-11-09 |
2015-09-15 |
Genvec, Inc. |
Methods of propagating monkey adenoviral vectors
|
WO2011057254A2
(fr)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vaccins à base de vecteur adénoviral simien
|
EP2536829B1
(fr)
|
2010-02-15 |
2016-04-06 |
Crucell Holland B.V. |
Procédé de production de vecteurs adénoviraux Ad26
|
WO2011116189A1
(fr)
|
2010-03-17 |
2011-09-22 |
Cornell University |
Vaccin adénoviral dissocié contre les drogues toxicomanogènes
|
BR112012024166A2
(pt)
|
2010-03-23 |
2022-09-27 |
Intrexon Corp |
Vetores condicionalmente expressando proteínas terapêuticas, células hospedeiras compreendendo os vetores, e usos dos mesmos
|
WO2012021730A2
(fr)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Vaccin contre le virus syncytial respiratoire (vsr)
|
CN103118702A
(zh)
|
2010-09-20 |
2013-05-22 |
克鲁塞尔荷兰公司 |
活动性结核病的治疗性接种
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
WO2012083297A2
(fr)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Vecteurs adénoviraux avec régions d'hexon modifiées
|
EP2654786B1
(fr)
|
2010-12-20 |
2019-02-20 |
GenVec, Inc. |
Vaccin contre la dengue à base d'un vecteur adénoviral
|
CN103534355A
(zh)
|
2011-03-04 |
2014-01-22 |
英特瑞克斯顿股份有限公司 |
条件性表达蛋白质的载体
|
WO2012162428A1
(fr)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Primovaccination-rappel pour infection virale
|
IN2014DN03005A
(fr)
|
2011-10-05 |
2015-05-08 |
Genvec Inc |
|
EP2764011B1
(fr)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Vaccin contre le virus respiratoire syncytial à base d'un vecteur adénoviral
|
EP2764014B1
(fr)
|
2011-10-05 |
2022-02-09 |
GenVec, Inc. |
Vecteurs adénoviraux et procédés d'utilisation
|
US9629906B2
(en)
|
2011-10-05 |
2017-04-25 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
WO2013074501A1
(fr)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
|
US20150157700A1
(en)
|
2012-02-02 |
2015-06-11 |
GanVec, Inc. |
Adenoviral vector-based malaria vaccine
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
EA034284B1
(ru)
|
2012-03-12 |
2020-01-24 |
Янссен Вэксинс Энд Превеншн Б.В. |
Частицы рекомбинантного трансгенсодержащего аденовируса с 5'-концевыми нуклеотидами ctatctat
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2827894B1
(fr)
|
2012-03-22 |
2017-05-17 |
Janssen Vaccines & Prevention B.V. |
Vaccin contre le vrs
|
WO2013181128A1
(fr)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Vecteurs adénoviraux de sérotype 28 modifiés
|
EP2855511B1
(fr)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Vaccin contre le virus de l'herpes simplex
|
PT2988780T
(pt)
|
2013-04-25 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
|
WO2014202570A1
(fr)
|
2013-06-17 |
2014-12-24 |
Crucell Holland B.V. |
Polypeptides f solubles et stabilisés du vrs en conformation pré-fusion
|
DK3046536T3
(en)
|
2013-09-19 |
2019-03-11 |
Janssen Vaccines & Prevention Bv |
IMPROVED ADENOVIRUS FORMULATIONS
|
EP3189067B1
(fr)
|
2014-09-04 |
2021-05-19 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Protéines de l'enveloppe du vih-1 et leur utilisation
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
NZ730802A
(en)
|
2014-11-04 |
2021-12-24 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv16 vaccines
|
EP3236998A1
(fr)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Protéines du métapneumovirus f recombinant et leur utilisation
|
JP7020917B2
(ja)
|
2015-01-20 |
2022-02-16 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
キメラrsv/bpiv3 fタンパクを発現する組換えヒト/ウシパラインフルエンザウイルス3(b/hpiv3)およびその使用
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
WO2016146844A1
(fr)
|
2015-03-18 |
2016-09-22 |
Janssen Vaccines & Prevention B.V. |
Dosages pour systèmes d'expression de recombinaison
|
SI3283634T1
(sl)
|
2015-04-14 |
2019-08-30 |
Janssen Vaccines & Prevention B.V. |
Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
|
BR112017027448A2
(pt)
|
2015-07-07 |
2018-09-04 |
Janssen Vaccines & Prevention Bv |
vacina contra rsv
|
CA2991540A1
(fr)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Polypeptides du virus respiratoire syncytial pre-fusion solubles stabilises
|
JP6470872B2
(ja)
|
2015-08-20 |
2019-02-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
治療用hpv18ワクチン
|
US20180280519A1
(en)
|
2015-10-06 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Methods for preventing plastic-induced degradation of biologicals
|
WO2017139392A1
(fr)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protéines d'enveloppe du vih-1 recombinantes et leur utilisation
|
US10808011B2
(en)
|
2016-03-09 |
2020-10-20 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant HIV-1 envelope proteins and their use
|
MA43762A
(fr)
|
2016-04-05 |
2021-04-21 |
Janssen Vaccines & Prevention Bv |
Vaccin contre le rsv
|
US11155583B2
(en)
|
2016-04-05 |
2021-10-26 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
BR112018072372A2
(pt)
|
2016-05-02 |
2019-02-19 |
Janssen Vaccines & Prevention B.V. |
combinações de vacina terapêutica contra o hpv
|
CA3025441A1
(fr)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Proteines f du vrs de pre-fusion stabilisees
|
MX2018015540A
(es)
|
2016-06-20 |
2019-04-11 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
EP3484506A1
(fr)
|
2016-07-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Vaccins contre le hpv
|
CA3038968A1
(fr)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovecteurs pour l'administration d'un materiel genetique therapeutique dans des lymphocytes t
|
US11602559B2
(en)
|
2016-10-03 |
2023-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV-1 Env fusion peptide immunogens and their use
|
EP3532095A1
(fr)
|
2016-10-25 |
2019-09-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Protéines de spicule de coronavirus de préfusion et utilisation associée
|
WO2018109220A2
(fr)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Nouvelles protéines f du vrs de pré-fusion recombinant et leurs utilisations
|
AU2018217935B2
(en)
|
2017-02-09 |
2020-04-30 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
US11235056B2
(en)
|
2017-03-24 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of HIV-1 gp120 and their use
|
EP3624844A1
(fr)
|
2017-05-17 |
2020-03-25 |
Janssen Vaccines & Prevention B.V. |
Procédés et compositions pour induire une immunité protectrice contre l'infection par le vrs
|
MX2020002876A
(es)
|
2017-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention Bv |
Metodo para la induccion segura de inmunidad contra el vsr.
|
EP3697440A1
(fr)
|
2017-10-16 |
2020-08-26 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Protéines d'enveloppe recombinées du vih-1 et leur utilisation
|
JP7438943B2
(ja)
|
2017-10-31 |
2024-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルス及びその用途
|
SG11202003290RA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
SG11202003398SA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and uses thereof
|
KR20200077559A
(ko)
|
2017-10-31 |
2020-06-30 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
SG11202006399VA
(en)
|
2018-01-23 |
2020-08-28 |
Janssen Vaccines & Prevention Bv |
Influenza virus vaccines and uses thereof
|
KR20200128703A
(ko)
|
2018-03-06 |
2020-11-16 |
프레시전 인코포레이티드 |
B형 간염 백신 및 이의 용도
|
CA3117390A1
(fr)
|
2018-10-22 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Proteine gp120 de recombinaison a deletion de la boucle v1
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020263900A1
(en)
|
2019-04-25 |
2021-10-14 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
MX2021013947A
(es)
|
2019-05-15 |
2021-12-14 |
Janssen Vaccines & Prevention Bv |
Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
BR122024002387A2
(pt)
*
|
2019-05-30 |
2024-03-12 |
Gritstone Bio, Inc. |
Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
|
WO2021043869A1
(fr)
|
2019-09-05 |
2021-03-11 |
Janssen Vaccines & Prevention B.V. |
Vaccins contre le virus de la grippe et leurs utilisations
|
MX2022004028A
(es)
|
2019-10-03 |
2022-05-02 |
Janssen Vaccines & Prevention Bv |
Vectores de adenovirus y usos de los mismos.
|
WO2021072129A2
(fr)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Protéines contenant de multiples acides aminés non naturels différents et procédés de fabrication et d'utilisation de telles protéines
|
PE20221182A1
(es)
|
2019-11-18 |
2022-08-05 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos
|
JP2023513693A
(ja)
|
2020-02-11 |
2023-04-03 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
SARS-CoV-2ワクチン
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
EP4135757A1
(fr)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Vaccins à base de psma et de steap1 et leurs utilisations
|
US20230174587A1
(en)
|
2020-04-29 |
2023-06-08 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant human metapneumovirus f proteins and their use
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
WO2022009051A1
(fr)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Procédé de détermination de la réactivité à un traitement du cancer de la prostate
|
EP4175721A1
(fr)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Néo-antigènes prostatiques et leurs utilisations
|
WO2022035860A2
(fr)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vaccins à adénovirus de type 4 aptes à la réplication exprimant des protéines d'enveloppe du vih et leur utilisation
|
WO2022232648A1
(fr)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Complexe de glycoprotéine du virus de lassa stabilisé par préfusion et son utilisation
|
CA3228275A1
(fr)
|
2021-08-03 |
2023-02-09 |
Genoveffa Franchini |
Vaccination contre le vih-1 et microbicide samt-247 pour prevenir une infection par le vih-1
|
WO2023091696A1
(fr)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Système d'administration d'adénovirus pour le traitement du cancer
|
WO2023192835A1
(fr)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ectodomaines de l'enveloppe du vih-1 recouverts d'une base et leur utilisation
|
WO2023196898A1
(fr)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptides mimétiques de la bêta globine et leur utilisation
|
EP4338727A1
(fr)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Formulations d'adénovirus
|